These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14709374)

  • 21. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
    Franceschini G; Cassinotti M; Vecchio G; Gianfranceschi G; Pazzucconi F; Murakami T; Sirtori M; D'Acquarica AL; Sirtori CR
    Arterioscler Thromb; 1994 Oct; 14(10):1569-75. PubMed ID: 7918306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio.
    Junyent M; Zambón D; Gilabert R; Cofán M; Núñez I; Ros E
    Atherosclerosis; 2008 Apr; 197(2):740-6. PubMed ID: 17698072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease.
    Miyazaki T; Shimada K; Sato O; Kotani K; Kume A; Sumiyoshi K; Sato Y; Ohmura H; Watanabe Y; Mokuno H; Daida H
    Atherosclerosis; 2005 Mar; 179(1):139-45. PubMed ID: 15721020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic consequences of genetic heterogeneity of lipoprotein composition (lipoprotein heterogeneity).
    Brunzell JD; Chait A; Albers JJ; Foster DM; Failor RA; Bierman EL
    Am Heart J; 1987 Feb; 113(2 Pt 2):583-8. PubMed ID: 3812212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia.
    Brouwers MC; van Greevenbroek MM; Vermeulen VM; van Lin JM; van der Kallen CJ; de Bruin TW
    Clin Sci (Lond); 2007 Nov; 113(9):375-81. PubMed ID: 17564583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased arterial stiffness in familial combined hyperlipidemia.
    Brouwers MC; Reesink KD; van Greevenbroek MM; Meinders JM; van der Kallen CJ; Schaper N; Hoeks AP; Stehouwer CD
    J Hypertens; 2009 May; 27(5):1009-16. PubMed ID: 19402225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.
    Hokanson JE; Austin MA; Zambon A; Brunzell JD
    Arterioscler Thromb; 1993 Mar; 13(3):427-34. PubMed ID: 8443147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia.
    Hoffer MJ; Snieder H; Bredie SJ; Demacker PN; Kastelein JJ; Frants RR; Stalenhoef AF
    Atherosclerosis; 2000 Aug; 151(2):443-50. PubMed ID: 10924721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia.
    Austin MA; Brunzell JD; Fitch WL; Krauss RM
    Arteriosclerosis; 1990; 10(4):520-30. PubMed ID: 2369363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families.
    Pajukanta P; Porkka KV; Antikainen M; Taskinen MR; Perola M; Murtomäki-Repo S; Ehnholm S; Nuotio I; Suurinkeroinen L; Lahdenkari AT; Syvänen AC; Viikari JS; Ehnholm C; Peltonen L
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):841-50. PubMed ID: 9157946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations.
    Valdemarsson S; Hansson P; Hedner P; Nilsson-Ehle P
    Acta Endocrinol (Copenh); 1983 Sep; 104(1):50-6. PubMed ID: 6624364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-heparin plasma lipoprotein and hepatic lipases. Relationships to high density lipoprotein cholesterol and to apolipoprotein CII in familial hyperalphalipoproteinemic and in normal subjects.
    Taskinen MR; Glueck CJ; Kashyap ML; Srivastava LS; Hynd BA; Perisutti G; Robinson K; Kinnunen PJ; Kuusi T
    Atherosclerosis; 1980 Oct; 37(2):247-56. PubMed ID: 7426098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
    Turk Z; Mrzljak V; Turk N; Metelko Z
    Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small dense LDL-cholesterol determined by a simple precipitation assay for screening familial combined hyperlipidemia.
    Hirano T; Nohtomi K; Sato Y; Kamata K; Ito Y
    Atherosclerosis; 2009 Aug; 205(2):603-7. PubMed ID: 19201411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.
    Holvoet P; Vanhaecke J; Janssens S; Van de Werf F; Collen D
    Circulation; 1998 Oct; 98(15):1487-94. PubMed ID: 9769301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial combined hyperlipidemia (FCHL) in children: the significance of early development of hyperapoB lipoproteinemia, obesity and aging.
    Kuromori Y; Okada T; Iwata F; Hara M; Noto N; Harada K
    J Atheroscler Thromb; 2002; 9(6):314-20. PubMed ID: 12560593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating malondialdehyde-modified LDL-related variables and coronary artery stenosis in asymptomatic patients with type 2 diabetes.
    Fujihara K; Suzuki H; Sato A; Kodama S; Heianza Y; Saito K; Iwasaki H; Kobayashi K; Yatoh S; Takahashi A; Yahagi N; Yagyu H; Sone H; Shimano H
    J Diabetes Res; 2015; 2015():507245. PubMed ID: 25883985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Malondialdehyde Low-Density Lipoprotein Stratified by Low-Density Lipoprotein Cholesterol.
    Moriyama K; Takahashi E
    Clin Lab; 2017 Jul; 63(7):1179-1186. PubMed ID: 28792690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of age and relative weight on the presentation of familial combined hyperlipidemia in childhood.
    Shamir R; Tershakovec AM; Gallagher PR; Liacouras CA; Hayman LL; Cortner JA
    Atherosclerosis; 1996 Mar; 121(1):85-91. PubMed ID: 8678927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia.
    Vakkilainen J; Pajukanta P; Cantor RM; Nuotio IO; Lahdenperä S; Ylitalo K; Pihlajamäki J; Kovanen PT; Laakso M; Viikari JS; Peltonen L; Taskinen MR
    Eur J Hum Genet; 2002 Sep; 10(9):547-52. PubMed ID: 12173032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.